Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Bolt Biotherapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.23
1.26
5.73
7.88
7.69
7.7
Research and development
40.4
75.7
73.1
61.5
57.5
28.5
General and administrative
9.06
18.4
22.9
22.5
18.5
13.8
Operating expenses
49.4
94
96.1
84.1
80.7
43.8
Operating income
-49.2
-92.8
-90.3
-76.2
-73
-36.1
Other non-operating income
-11.5
-5.8
2.22
7
9.93
2.74
Pre-tax income
-63.1
-33.4
Income tax
0
0
0
0
0
0
Net income
-60.7
-98.6
-88.1
-69.2
-63.1
-33.4
EBITDA
-48.6
-91.6
-88.7
-74.3
-71.3
-34.8
EPS, basic
-578.85
-59.51
-47.29
-36.67
-33.06
-17.85
EPS, diluted
-578.85
-59.51
-47.29
-36.67
-33.06
-17.85
Shares, basic (weighted)
0.1
1.66
1.86
1.89
1.91
1.87
Shares, diluted (weighted)
0.1
1.66
1.86
1.89
1.91
1.87
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
5.54
27.4
9.24
10.8
7.21
11.7
Short-term investments
17.3
159
160
91.4
40.1
15.8
Other current assets
2.52
2.94
3.86
3.52
2.71
2.56
Total current assets
25.4
189
173
106
50.8
30.3
Property, plant and equipment
4.08
6.16
6.45
4.96
3.14
1.25
Lease right-of-use assets
12.3
24.4
22.1
19.1
21.8
19.2
Long-term investments
85.3
23.9
26.4
22.9
4.34
Other non-current assets
0.91
1.04
1.03
1.82
0.06
0.14
Total assets
46.5
308
228
160
99.6
56.7
Accounts payable
1.6
3.57
3.59
2.99
1.51
1.44
Accrued liabilities
2.89
4.89
4.8
5.82
4.2
1.64
Deferred revenue
1.5
2.87
1.4
2.2
3.02
0.45
Total current liabilities
11.3
21.3
23.1
20.5
15.9
8.44
Lease liabilities
9.38
21.9
20.2
17.4
23
20.1
Other non-current liabilities
0.33
0.21
0.04
0.04
0
0.13
Total liabilities
46.2
57.6
56.3
47
42.4
30.2
Paid-in capital
3.45
457
468
477
485
487
Retained earnings
-108
-207
-295
-364
-427
-461
Other comprehensive income
-0.32
-0.92
0.04
0.1
-0.02
Shareholders' equity
-105
250
172
113
57.2
26.5
Total equity
-105
250
172
113
57.2
26.5
Total liabilities and equity
46.5
308
228
160
99.6
56.7
Shares outstanding
0.11
1.87
1.89
1.9
1.92
1.92
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-60.7
-98.6
-88.1
-69.2
-63.1
-33.4
Depreciation and amortization
0.61
1.19
1.67
1.85
1.78
1.29
Stock-based compensation
1.42
8.5
9.58
9.22
7.41
2.78
Change in payables
2.88
6.68
2.77
-3.41
-4.88
-5.43
Cash from operations
-47.3
-57.1
-76.5
-69.5
-61.3
-39.9
Capital expenditures
-3.26
-2.34
-1.95
-0.21
-0.04
-0.07
Purchases of investments
-33.2
-313
-181
-165
-88.9
-29
Sales and maturities of investments
15.9
83.5
241
236
146
72.4
Cash from investing
-20.6
-232
57.9
71
57.6
44.3
Stock issued
0.29
1.25
0.5
0.25
0.11
0.02
Cash from financing
39.6
311
0.5
0.25
0.11
0.02
Net change in cash
-28.3
21.8
-18.1
1.77
-3.61
4.47
Free cash flow
-50.6
-59.4
-78.5
-69.7
-61.3
-39.9
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.58 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-654.5%
Operating income / revenue.
EBITDA margin
-634.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-611.5%
Net income / revenue.
Operating cash flow margin
-669.2%
Cash from operations / revenue.
Return on equity (ROE)
-227.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-71.2%
Net income / average total assets.
R&D / revenue
457.5%
Research and development expense / revenue.
Stock-based pay / revenue
54.1%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
20.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
0.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
10.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
101.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-53.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-46.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-43.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-37.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
4.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
-2.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
77.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.61x
Current assets / current liabilities.
Quick ratio
2.24x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.24x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.78
Revenue / diluted weighted shares.
Operating cash flow per share
-$18.60
Cash from operations / diluted weighted shares.
Book value per share
$6.56
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.47x
Market cap / revenue.
P/B
0.55x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.55x
Market cap / tangible book value, when positive.
Earnings yield
-416.7%
Net income / market cap (the inverse of P/E).
What was Bolt Biotherapeutics, Inc.'s revenue in fiscal 2025?
Bolt Biotherapeutics, Inc. reported revenue of $7.7M for fiscal 2025, 0.1% higher than the year before.
Was Bolt Biotherapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $33.4M.
How much free cash flow did Bolt Biotherapeutics, Inc. generate in fiscal 2025?
Cash from operations of $39.9M minus capital expenditures of $72.0K left free cash flow of -$39.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.